Catalent Inc Stock Price, News & Analysis

Catalent, the global leader in enabling biopharma and consumer health partners, announced its executive leadership team will present at two investor conferences. The presentations will take place on June 7, 2022 at 1:00 p.m. ET during the William Blair Annual Growth Stock Conference, and on June 8, 2022 at 8:00 a.m. ET at the Jefferies 2022 Healthcare Conference. Live webcasts will be available on their investor site and can be replayed post-event. Catalent, recognized for accelerating partner programs and product launches, generated $4 billion in revenue in 2021.

Catalent, Inc. (CTLT) reported Q3'22 net revenue of $1.27 billion, a 21% increase from Q3'21, with organic growth at 20%. Net earnings stood at $141 million, down from $217 million a year prior, largely due to a prior gain from a business sale. Adjusted EBITDA for Q3'22 was $339 million, representing a 24% increase. The company updated its FY'22 guidance, projecting net revenue growth of 20-23% and Adjusted EBITDA growth of 24-28%. For FY'23, Catalent anticipates organic growth aligning with its long-term outlook of 8-10%.

Catalent (NYSE: CTLT) is set to release its financial results for the third quarter of fiscal year 2022, which ended on March 31, 2022, before market open on May 3, 2022. A webcast hosted by management will take place at 8:15 a.m. ET the same day, available on the company’s website. Catalent is a global leader in advanced delivery technologies and generated $4 billion in revenue in its 2021 fiscal year. Interested parties can access a supplemental slide presentation prior to the webcast.

Catalent, the global leader in biopharma, cell, gene, and consumer health solutions, will present virtually at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 10:30 a.m. ET. A live webcast of the presentation will be available at http://investor.catalent.com and can be replayed afterwards. Catalent is known for optimizing product development and supply, generating $4 billion in revenue in 2021, and supporting over 1,000 partner programs annually.

Catalent, Inc. (NYSE: CTLT) has released its Corporate Responsibility (CR) Report for fiscal year ending June 30, 2021, marking its third report since initiating its CR strategy. The report details achievements in innovation, quality, and sustainability, aligning with SASB standards and TCFD recommendations. Key highlights include a 15% reduction in Scope 2 carbon emissions and a commitment to reduce Scope 1 and 2 emissions by 42% by 2030. Catalent's philanthropic giving exceeded $1 million, focusing on community support and STEM education, alongside efforts to enhance diversity within its workforce.

DARTISLA ODT, the first FDA-approved orally disintegrating tablet of glycopyrrolate, is now available in the U.S. for adults to treat peptic ulcers. The product is accessible through prescription via Phil and retail pharmacies. Edenbridge Pharmaceuticals sponsors a Copay Program that enables eligible patients to acquire the medication for as little as $0. This innovative tablet is manufactured by Catalent using proprietary technology, allowing quick dissolution without water. The FDA approved this product on December 16, 2021.

Catalent, Inc. (CTLT) reported Q2'22 net revenue of $1.22 billion, a 34% increase year-over-year, with 32% organic growth. Net earnings reached $97 million, and Adjusted EBITDA rose to $310 million, up 39%. The company revised its fiscal guidance, projecting net revenue growth of 19-22% and Adjusted EBITDA growth of 23-27%. Catalent aims for over $7.5 billion in annual revenue by fiscal 2026, fueled by continued organic growth and acquisitions.

Catalent (NYSE: CTLT) will announce its financial results for the second quarter of fiscal year 2022, ending December 31, 2021, on February 1, 2022, before the market opens. A webcast hosted by management at 8:15 a.m. ET the same day will discuss these results. Interested parties can access the webcast on Catalent's website. The company generated $4 billion in revenue during its 2021 fiscal year and supports over 1,000 partner programs annually.

ElevateBio has appointed Andrew Sandford as the President of ElevateBio BaseCamp, its innovation center focused on cell and gene therapy. Sandford brings over 20 years of industry experience, previously serving as Global VP of Business Development at Catalent (NYSE: CTLT). His role will enhance the company’s manufacturing operations and cultivate strategic partnerships. ElevateBio aims to expand its process development and cGMP capabilities to drive innovation in cellular and genetic medicines, fostering growth and collaboration in the biotech sector.